SavedAdd your journal

Journals / Cukurova Medical Journal / 2020 / Cilt: 45 - Sayı: 2

Analysis of adverse drug reactions in hospitalized patients reported to pharmacovigilance center in a teaching hospital

Bir eğitim hastanesinde farmakovijilans merkezine yönlendirilen yatan hastalardaki advers ilaç reaksiyonlarının analizi

Zakir KHAN
Emine ÖZ EKEMEN
Olcay KIROĞLU
Yusuf KARATAŞ
Pages
556–561
Publication Date
2020-06-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Monitoring and management of severe and serious types of ADRs would be valuable for improved patient care.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: This study was carried out to assess the rate and pattern of adverse drug reactions (ADRs) reporting in hospitalized patients at a teaching hospital.
📊
Key Findings & Data:Results: A total of 61105 hospitalized patients were admitted to the hospital and only 20 spontaneous ADRS were submitted to (PVCP) with an incidence rate of 0.03%.
💡
Conclusion & Impact:Monitoring and management of severe and serious types of ADRs would be valuable for improved patient care.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Adverse drug reactions · antibiotics · pharmacovigilance

Abstract

Purpose: This study was carried out to assess the rate and pattern of adverse drug reactions (ADRs) reporting in hospitalized patients at a teaching hospital. Materials and Methods: A retrospective cross-sectional study was conducted in Balcalı Hospital at Adana, Turkey for one year. The reports were examined on the basis of demographics, ADRs type, causality, severity, seriousness, drug characteristics, and outcomes. WHO-UMC/ Naranjo algorithm scale, Hartwig and Siegel severity scale and pharmacovigilance contact point (PVCP) criteria were used to assess the causality, severity, and seriousness of ADRs respectively. Results: A total of 61105 hospitalized patients were admitted to the hospital and only 20 spontaneous ADRS were submitted to (PVCP) with an incidence rate of 0.03%. Of these, 18 eligible ADRs reporting forms were reviewed according to inclusion criteria. ADRs related to antibiotics (38.8%) were most frequently reported followed by antineoplastic agents (22.2%). Most of the ADRs were related to skin (33.3%). In causality assessment, almost 50% of the reported ADRs were possible and 55.5% were moderate in severity. Moreover, about 83.3% of the ADRs were found to be serious according to PVCP criteria. Among the total patients, 55.5% have recovered from the reactions. ADRs were reported by physicians (66.7%) followed by an assistant doctor (16.7%).Conclusion: This study shows that ADRs are a significant problem in hospitalized patients. Monitoring and management of severe and serious types of ADRs would be valuable for improved patient care.

Özet

Amaç: Bu çalışma, bir eğitim hastanesinde yatan hastalarda rapor edilen advers ilaç reaksiyonlarının (ADR) oranını ve şeklini değerlendirmek için yapılmıştır. Gereç ve Yöntem: Adana, Balcalı Hastanesi'nde bir yıllık retrospektif kesitsel bir çalışma yapıldı. ADR'lerin nedensellik, şiddet ve ciddiyetini değerlendirmek için WHO-UMC / Naranjo algoritma skalası, Hartwig ve Siegel şiddet skalası ve farmakovijilans temas noktası (PVCP) kriterleri kullanıldı. Bulgular: Toplam 61105 yatan hastadan 20 spontan ADRS vakası PVCP’ye sunulmuş olup insidansı %0.03’ e denk düşmektedir. Bunlardan 18 tanesi ADR bildirim formu dahil edilme kriterlerine göre uygun bulunmuştur. Antibiyotiklerle ilişkili ADR'ler (% 38.8) en sık bildirilirken antineoplastik ajanlar (% 22.2) idi. ADR'lerin çoğu deri ile ilişkiliydi (% 33.3). Nedensellik değerlendirmesinde, bildirilen ADR'lerin neredeyse %50'si mümkündür ve % 55.5'i orta ciddiyettedir. Ayrıca, ADR'lerin yaklaşık % 83.3'ünün PVCP kriterlerine göre ciddi olduğu bulunmuştur. Toplam hastalar arasında% 55.5'i reaksiyonlardan iyileşmiştir. ADR'ler doktorlar (% 66.7) ve ardından asistan doktor (% 16.7) tarafından rapor edilmiştir.Sonuç: Bu çalışma hastanede yatan hastalarda ADR'lerin önemli bir problem olduğunu göstermektedir. Şiddetli ve ciddi tipte ADR'lerin izlenmesi ve yönetimi, daha iyi hasta bakımı için değerli olacaktır.

🔖

Cite This Article

KHAN, Z., EKEMEN, E. Ö., KIROĞLU, O., KARATAŞ, Y. (2020). Analysis of adverse drug reactions in hospitalized patients reported to pharmacovigilance center in a teaching hospital. Cukurova Medical Journal, Cilt: 45 - Sayı: 2, 556–561. https://ajindex.com/articles/56176

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Giardina C, Cutroneo PM, Mocciaro E, Russo GT, Mandraffino G, Basile G et al. Adverse drug reactions in hospitalized patients: results of the FORWARD (facilitation of reporting in hospital ward) study. Front Pharmacol. 2018;9:350
  2. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356:1255-9
  3. Ozcan G, Aykac E, Kasap Y, Nemutlu NT, Sen E, Aydinkarahaliloglu ND. Adverse drug reaction reporting pattern in Turkey: analysis of the national database in the context of the first pharmacovigilance legislation. Drugs Real World Outcomes. 2016;3:33- 43
  4. Pathak AK, Kumar M, Dokania S, Mohan L, Dikshit H. A retrospective analysis of reporting of adverse drug reactions in a tertiary care teaching hospital: one year survey. J Clin Diagn Res. 2016;10(8):FC01-4
  5. Lazorou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. JAMA. 1998;279:1200-5
  6. Venkatasubbaiah M, Reddy PD, Satyanarayana SV. Analysis and reporting of adverse drug reactions at a tertiary care teaching hospital. Alexandria Med J. 2018;54:597-603
  7. Hussain R, Hassali MA. Current status and future prospects of pharmacovigilance in Pakistan. J Pharm Policy Pract, 2019;12:14
  8. World Health Organization (WHO). Pharmacovigilance: Ensuring the Safe Use of Medicines - WHO Policy Perspectives on Medicines. Geneva, WHO, 2004. 9. 18th ISoP Annual Meeting “Pharmacovigilance without borders” Geneva, Switzerland, 11–14 November, 2018. Drug Safety. 2018;41:1103-273
  9. World Health Organization (WHO) Pharmacovigilance.2004. https://www. who.int/medicines/areas/quality_safety/safety_effic acy/pharmvigi/en/. Accessed 15 November 2019
  10. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-45
  11. World Health Organization (WHO). The use of the WHO-UMC system for standardized case causality assessment. Uppsala, The Uppsala Monitoring Centre, 2005
  12. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49:2229-32
  13. World Health organization (WHO) ATC/DDD methodology. 2019-2020. https://www.whocc.no/atc_ddd_index/. Accessed 15 November 2019
  14. Carrasco-Garrido P, de Andrés LA, Barrera VH, Barrera VH, de Miguel GA, Jiménez-García R. Trends of adverse drug reactions relatedhospitalizations in Spain (2001-2006). BMC Health Serv Res. 2010;10:287. 16.